- Home
- AUGO vs JANX Comparison
AUGO vs JANX Comparison
Compare AUGO & JANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AUGO
- JANX
- Stock Information
- Founded
- AUGO 1946
- JANX 2017
- Country
- AUGO United States
- JANX United States
- Employees
- AUGO N/A
- JANX N/A
- Industry
- AUGO
- JANX Biotechnology: Pharmaceutical Preparations
- Sector
- AUGO
- JANX Health Care
- Exchange
- AUGO Nasdaq
- JANX Nasdaq
- Market Cap
- AUGO 1.8B
- JANX 1.5B
- IPO Year
- AUGO N/A
- JANX 2021
- Fundamental
- Price
- AUGO $25.24
- JANX $25.96
- Analyst Decision
- AUGO
- JANX Strong Buy
- Analyst Count
- AUGO 0
- JANX 8
- Target Price
- AUGO N/A
- JANX $90.63
- AVG Volume (30 Days)
- AUGO 565.6K
- JANX 839.1K
- Earning Date
- AUGO 08-05-2025
- JANX 08-06-2025
- Dividend Yield
- AUGO 3.57%
- JANX N/A
- EPS Growth
- AUGO N/A
- JANX N/A
- EPS
- AUGO N/A
- JANX N/A
- Revenue
- AUGO $623,889,000.00
- JANX $9,336,000.00
- Revenue This Year
- AUGO N/A
- JANX N/A
- Revenue Next Year
- AUGO N/A
- JANX $1,470.82
- P/E Ratio
- AUGO N/A
- JANX N/A
- Revenue Growth
- AUGO 38.03
- JANX 28.12
- 52 Week Low
- AUGO $23.50
- JANX $22.48
- 52 Week High
- AUGO $25.57
- JANX $71.71
- Technical
- Relative Strength Index (RSI)
- AUGO N/A
- JANX 53.36
- Support Level
- AUGO N/A
- JANX $25.81
- Resistance Level
- AUGO N/A
- JANX $27.31
- Average True Range (ATR)
- AUGO 0.00
- JANX 1.30
- MACD
- AUGO 0.00
- JANX 0.08
- Stochastic Oscillator
- AUGO 0.00
- JANX 45.02
About JANX Janux Therapeutics Inc.
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. Its proprietary technology has enabled the development of two distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr). The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.